|
1
|
De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, et al: Cancer survival in Europe 1999-2007 by country and age: Results of EUROCARE-5-a population-based study. Lancet Oncol. 15:23–34. 2014.
|
|
2
|
Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 46:765–781. 2010.
|
|
3
|
Huggins C, Stevens RE Jr and Hodges CV: Studies on prostatic cancer: II. the effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 43:209–223. 1941.
|
|
4
|
Sharifi N, Gulley JL and Dahut WL: Androgen deprivation therapy for prostate cancer. JAMA. 294:238–244. 2005.
|
|
5
|
Huggins C and Hodges CV: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 168:9–12. 2002.
|
|
6
|
Attar RM, Takimoto CH and Gottardis MM: Castration-resistant prostate cancer: Locking up the molecular escape routes. Clin Cancer Res. 15:3251–3255. 2009.
|
|
7
|
Furuhashi M and Hotamisligil GS: Fatty acid-binding proteins: Role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 7:489–503. 2008.
|
|
8
|
Haunerland NH and Spener F: Fatty acid-binding proteins-insights from genetic manipulations. Prog Lipid Res. 43:328–349. 2004.
|
|
9
|
Jing C, Beesley C, Foster CS, Chen H, Rudland PS, West DC, Fujii H, Smith PH and Ke Y: Human cutaneous fatty acid-binding protein induces metastasis by up-regulating the expression of vascular endothelial growth factor gene in rat Rama 37 model cells. Cancer Res. 61:4357–4364. 2001.
|
|
10
|
Jing C, Beesley C, Foster CS, Rudland PS, Fujii H, Ono T, Chen H, Smith PH and Ke Y: Identification of the messenger RNA for human cutaneous fatty acid-binding protein as a metastasis inducer. Cancer Res. 60:2390–2398. 2000.
|
|
11
|
Adamson J, Morgan EA, Beesley C, Mei Y, Foster CS, Fujii H, Rudland PS, Smith PH and Ke Y: High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity. Oncogene. 22:2739–2749. 2003.
|
|
12
|
Morgan EA, Forootan SS, Adamson J, Foster CS, Fujii H, Igarashi M, Beesley C, Smith PH and Ke Y: Expression of cutaneous fatty acid-binding protein (C-FABP) in prostate cancer: Potential prognostic marker and target for tumourigenicity-suppression. Int J Oncol. 32:767–775. 2008.
|
|
13
|
Al-Jameel W, Gou X, Forootan SS, Al Fayi MS, Rudland PS, Forootan FS, Zhang J, Cornford PA, Hussain SA and Ke Y: Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5. Oncotarget. 8:31041–31056. 2017.
|
|
14
|
Berger WT, Ralph BP, Kaczocha M, Sun J, Balius TE, Rizzo RC, Haj-Dahmane S, Ojima I and Deutsch DG: Targeting fatty acid binding protein (FABP) anandamide transporters-a novel strategy for development of anti-inflammatory and anti-nociceptive drugs. PLoS One. 7:e509682012.
|
|
15
|
Lehmann F, Haile S, Axen E, Medina C, Uppenberg J, Svensson S, Lundbäck T, Rondahl L and Barf T: Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 14:4445–4448. 2004.
|
|
16
|
Kaczocha M, Rebecchi MJ, Ralph BP, Teng YH, Berger WT, Galbavy W, Elmes MW, Glaser ST, Wang L, Rizzo RC, et al: Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia. PLoS One. 9:e942002014.
|
|
17
|
Thanos PK, Clavin BH, Hamilton J, O'Rourke JR, Maher T, Koumas C, Miao E, Lankop J, Elhage A, Haj-Dahmane S, et al: Examination of the addictive and behavioral properties of fatty acid-binding protein inhibitor SBFI26. Front Psychiatry. 7:542016.
|
|
18
|
Myers JS, von Lersner AK and Sang QX: Proteomic upregulation of fatty acid synthase and fatty acid binding protein 5 and identification of cancer- and race-specific pathway associations in human prostate cancer tissues. J Cancer. 7:1452–1464. 2016.
|
|
19
|
Kawaguchi K, Kinameri A, Suzuki S, Senga S, Ke Y and Fujii H: The cancer-promoting gene fatty acid-binding protein 5 (FABP5) is epigenetically regulated during human prostate carcinogenesis. Biochem J. 473:449–461. 2016.
|
|
20
|
Zhang J, He G, Jin X, Alenezi BT, Naeem AA, Abdulsamad SA and Ke Y: Molecular mechanisms on how FABP5 inhibitors promote apoptosis-induction sensitivity of prostate cancer cells. Cell Biol Int. 47:929–942. 2023.
|
|
21
|
Forootan FS, Forootan SS, Gou X, Yang J, Liu B, Chen D, Al Fayi MS, Al-Jameel W, Rudland PS, Hussain SA and Ke Y: Fatty acid activated PPARγ promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter. Oncotarget. 7:9322–9339. 2016.
|
|
22
|
Forootan FS, Forootan SS, Malki MI, Chen D, Li G, Lin K, Rudland PS, Foster CS and Ke Y: The expression of C-FABP and PPARγ and their prognostic significance in prostate cancer. Int J Oncol. 44:265–275. 2014.
|
|
23
|
Bao Z, Malki MI, Forootan SS, Adamson J, Forootan FS, Chen D, Foster CS, Rudland PS and Ke Y: A novel cutaneous fatty acid-binding protein-related signaling pathway leading to malignant progression in prostate cancer cells. Genes Cancer. 4:297–314. 2013.
|
|
24
|
Berthon P, Cussenot O, Hopwood L, Leduc A and Maitland N: Functional expression of sv40 in normal human prostatic epithelial and fibroblastic cells-differentiation pattern of nontumorigenic cell-lines. Int J Oncol. 6:333–343. 1995.
|
|
25
|
Cussenot O, Berthon P, Berger R, Mowszowicz I, Faille A, Hojman F, Teillac P, Le Duc A and Calvo F: Immortalization of human adult normal prostatic epithelial cells by liposomes containing large T-SV40 gene. J Urol. 146:881–886. 1991.
|
|
26
|
Cussenot O, Berthon P, Cochand-Priollet B, Maitland NJ and Le Duc A: Immunocytochemical comparison of cultured normal epithelial prostatic cells with prostatic tissue sections. Exp Cell Res. 214:83–92. 1994.
|
|
27
|
Sramkoski RM, Pretlow TG II, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D and Jacobberger JW: A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim. 35:403–409. 1999.
|
|
28
|
Stone KR, Mickey DD, Wunderli H, Mickey GH and Paulson DF: Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer. 21:274–281. 1978.
|
|
29
|
Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME and Hart IR: Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res. 44:3522–3529. 1984.
|
|
30
|
Leszczyński P, Śmiech M, Salam Teeli A, Haque E, Viger R, Ogawa H, Pierzchała M and Taniguchi H: Deletion of the Prdm3 gene causes a neuronal differentiation deficiency in P19 Cells. Int J Mol Sci. 21:71922020.
|
|
31
|
Doudna JA and Charpentier E: Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 346:12580962014.
|
|
32
|
Unniyampurath U, Pilankatta R and Krishnan MN: RNA interference in the age of CRISPR: Will CRISPR interfere with RNAi? Int J Mol Sci. 17:2912016.
|
|
33
|
Tyumentseva MA, Tyumentsev AI and Akimkin VG: Protocol for assessment of the efficiency of CRISPR/Cas RNP delivery to different types of target cells. PLoS One. 16:e02598122021.
|
|
34
|
Xu X, Wan T, Xin H, Li D, Pan H, Wu J and Ping Y: Delivery of CRISPR/Cas9 for therapeutic genome editing. J Gene Med. 21:e31072019.
|
|
35
|
Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM and McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 47:3239–3245. 1987.
|
|
36
|
Fisher PR, Merkl R and Gerisch G: Quantitative analysis of cell motility and chemotaxis in Dictyostelium discoideum by using an image processing system and a novel chemotaxis chamber providing stationary chemical gradients. J Cell Biol. 108:973–984. 1989.
|
|
37
|
Graham FL and van der Eb AJ: Transformation of rat cells by DNA of human adenovirus 5. Virology. 54:536–539. 1973.
|
|
38
|
Reitman S and Frankel S: A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 28:56–63. 1957.
|
|
39
|
Al Fayi MS, Gou X, Forootan SS, Al-Jameel W, Bao Z, Rudland PR, Cornford PA, Hussain SA and Ke Y: The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance. Oncotarget. 7:82783–82797. 2016.
|
|
40
|
Wadosky KM and Koochekpour S: Androgen receptor splice variants and prostate cancer: From bench to bedside. Oncotarget. 8:18550–18576. 2017.
|
|
41
|
Antonarakis ES, Nakazawa M and Luo J: Resistance to androgen-pathway drugs in prostate cancer. N Engl J Med. 371:22342014.
|
|
42
|
Al-Jameel W, Gou X, Jin X, Zhang J, Wei Q, Ai J, Li H, Al-Bayati A, Platt-Higgins A, Pettitt A, et al: Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ. Genes Cancer. 10:80–96. 2019.
|
|
43
|
Lanningham-Foster L, Green CL, Langkamp-Henken B, Davis BA, Nguyen KT, Bender BS and Cousins RJ: Overexpression of CRIP in transgenic mice alters cytokine patterns and the immune response. Am J Physiol Endocrinol Metab. 282:E1197–E1203. 2002.
|
|
44
|
Mitchell JA, Shynlova O, Langille BL and Lye SJ: Mechanical stretch and progesterone differentially regulate activator protein-1 transcription factors in primary rat myometrial smooth muscle cells. Am J Physiol Endocrinol Metab. 287:E439–E445. 2004.
|
|
45
|
Papa M, Boscia F, Canitano A, Castaldo P, Sellitti S, Annunziato L and Taglialatela M: Expression pattern of the ether-a-gogo-related (ERG) K+ channel-encoding genes ERG1, ERG2, and ERG3 in the adult rat central nervous system. J Comp Neurol. 466:119–135. 2003.
|
|
46
|
Howe BM, Bruno SB, Higgs KA, Stigers RL and Cunningham JT: FosB expression in the central nervous system following isotonic volume expansion in unanesthetized rats. Exp Neurol. 187:190–198. 2004.
|
|
47
|
Shin SH, Kim I, Lee JE, Lee M and Park JW: Loss of EGR3 is an independent risk factor for metastatic progression in prostate cancer. Oncogene. 39:5839–5854. 2020.
|
|
48
|
Christoforou P, Christopoulos PF and Koutsilieris M: The role of estrogen receptor β in prostate cancer. Mol Med. 20:427–434. 2014.
|
|
49
|
Mansi R, Fleischmann A, Macke HR and Reubi JC: Targeting GRPR in urological cancers-from basic research to clinical application. Nat Rev Urol. 10:235–244. 2013.
|
|
50
|
Meshulam T, Simard JR, Wharton J, Hamilton JA and Pilch PF: Role of caveolin-1 and cholesterol in transmembrane fatty acid movement. Biochemistry. 45:2882–2893. 2006.
|
|
51
|
Trigatti BL, Anderson RG and Gerber GE: Identification of caveolin-1 as a fatty acid binding protein. Biochem Biophys Res Commun. 255:34–39. 1999.
|
|
52
|
Edwards PA, Kast HR and Anisfeld AM: BAREing it all: The adoption of LXR and FXR and their roles in lipid homeostasis. J Lipid Res. 43:2–12. 2002.
|
|
53
|
Nath A and Chan C: Genetic alterations in fatty acid transport and metabolism genes are associated with metastatic progression and poor prognosis of human cancers. Sci Rep. 6:186692016.
|
